摘要
索拉非尼(sorafenib)是一种口服多激酶抑制剂,为一新的多靶点抗肿瘤药,能抑制肿瘤血管形成及肿瘤细胞增殖。临床研究表明,索拉非尼能有效治疗肾细胞癌晚期患者,并延长其无疾病进展期和总生存期,索拉非尼对其他癌症的作用也正在研究中。索拉非尼的常见不良反应有皮疹、手足综合征、高血压及腹泻等。
Sorafenib, an oral multikinase inhibitor, is a novel multi-targeted antineoplastic agent that can inhibit angiogenesis and tumor cell proliferation. Clinical studies have showed that sorafenib is effective in treatment of patients with advanced renal cell carcinoma and in prolongation of progression-free survival （PFS） and overall survival （OS） of the patients. The effects of sorafenib on some other cancers are also under investigations. The common adverse reactions to sorafenib are rash, hand-foot syndrome, hypertension, diarrhea, and so on.
出处
《药物不良反应杂志》
2007年第3期153-157,共5页
Adverse Drug Reactions Journal
